'Golden age' weight-loss pill that mimics gastric bypass op is hailed a 'miracle' - and said to be better than fat jabs
A pill that mimics the effect of a gastric bypass has been touted as the latest weight loss miracle – and may even be more effective than fat jabs in the long term.
The capsules produce a temporary coating in the gut that prevents food from being absorbed, forcing it into the lower intestine and triggering hormones that make you feel full.
Its manufacturers say it may have advantages over weight-loss injections such as Ozempic and Mounjaro, including having fewer side effects and being easier to take.
It is also far safer and less invasive than actual gastric bypass surgery.
Rahul Dhanda, chief executive of Syntis Bio, makers of the pill, said: 'The problem is [fat jabs] are not very tolerable and patients want to come off them.
'You want to have a long-term maintenance therapy, and an oral pill is the rational choice because it's simple, tolerable and safe.
'What we're seeing now is patients and clinics being more focused on having something safe and sustainable to keep on a manageable, sustainable weight-loss path.
'I anticipate the side effects to be minimal to none, and we haven't seen any yet in human tests. That is because it doesn't enter the bloodstream like injections do.
'It's a mechanical molecule, so it's like we're inserting a stent, as opposed to a drug that is acting with the target, and also off the target.'
By binding to the mucous membrane lining of the duodenum - the top of the intestine near the stomach - the pills create a barrier that stops calories being absorbed.
It forces food directly into the lower part of the digestive system, the pills set off a 'cascade' of hormones including GLP-1, the same chemical mimicked by semaglutide jab Wegovy.
It also causes the body to stop producing ghrelin, which makes you feel hungry, and start producing leptin, which makes you feel satisfied.
The person taking the pill feels full more quickly and stops eating.
The coating created by the pill sheds naturally after about 24 hours, leaving no trace.
The effect is similar to gastric bypass, in which surgeons make the stomach smaller and shorten the small intestine, changing how the body absorbs food and leaving people feeling fuller after eating less.
In rats, the drug caused the animals to lose 1 per cent of their bodyweight per week while preserving 100 per cent of their lean muscle mass.
Trials in humans have not studied weight loss but found the pills cause no harmful side effects.
If they prove effective in further trials, the pills could help patients maintain a healthy weight after intensive weight-loss with jabs, or replace the injections entirely.
Dr Louis Aronne of Weill Cornell Medicine in New York City told the conference that a 'golden age' of treatment had begun with these new drugs.
The Times reported he was pushing for health providers, including the NHS, to 'roll them out at scale', addding: 'I think use of drugs like this will prevent the need for many other medications, procedures, and surgeries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
19 minutes ago
- The Independent
Mounjaro weight loss jab: All you need to know
GPs in England will be able to prescribe weight loss jabs for the first time on the NHS on Monday, as the health service begins its mass rollout. Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
Telegraph
an hour ago
- Telegraph
GPs to roll out weight-loss jabs to 250k people
GPs will be able to prescribe weight-loss jabs to those who need them most from Monday. Almost a quarter of million people across England will be prescribed Mounjaro, made by the pharmaceutical firm Lilly, on the NHS over the next three years. The injections, which also include Wegovy, made by Novo Nordisk, are currently used by about 1.5 million people, but the majority of those patients access the medicine privately. Wes Streeting, the Health Secretary, said he was determined to make 'revolutionary modern treatments' available to everyone and 'not just those who can afford to pay'. He added: 'Obesity is now one of the leading causes of ill-health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.' He said making the jabs available via general practices was the 'beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver'. But GPs have voiced concerns about the extra workload and pressure it will put them under. Pharmacy leaders have said pressure on supplies will also be a factor, as it has been since the drugs were first licenced in the UK for weight loss. The jabs were initially used to treat diabetes, but as well as lowering blood sugar levels they also slow down how quickly food is digested and make people feel fuller so they eat less, helping them to lose weight. Patients previously needed to access the drugs through a special weight-loss service on the NHS. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40, meaning they are 'severely obese' and it is having a drastic impact on their health. They must also have at least four other health problems linked to obesity, such as type 2 diabetes, high blood pressure, heart disease and obstructive sleep apnoea. Prof Kamila Hawthorne, who chairs the Royal College of GPs, said: 'While we recognise the potential benefits of weight-loss drugs, we know many GPs are concerned about the implications of the rollout of weight-loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased rollout of Mounjaro as a treatment for weight loss. 'As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow.' Dr Hawthorne said there is no 'one size fits all approach' to weight loss, and that the rollout of the jabs should not 'come at the expense of other weight-loss service'. She said the rollout would need to be 'consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit'. Olivier Picard, chairman of the National Pharmacy Association, said demand for the jabs 'continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial enquiries to access these treatments privately'. He said the industry is expecting 'to see prescription volumes increase rapidly', but warned: 'NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'The biggest concern we have is that prescribing these medications alone misses the point. They should be part of a comprehensive weight management strategy, combining lifestyle coaching, exercise, and nutritional guidance. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Dr Claire Fuller, the primary care medical director at NHS England, said: 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill-health – and greater access to weight-loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight-loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Around 29 per cent of the adult population in the UK is obese.
Daily Mirror
an hour ago
- Daily Mirror
'King Kong' of weight loss jabs available on NHS to those in need from today
Around 220,000 people with "greatest need" are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years Hundreds of thousands of NHS patients will benefit from the 'King Kong' of weight loss jabs from today. Around 220,000 in "greatest need" are expected to receive Mounjaro in the mass roll out over the next three years. It is the brand name for the drug tirzepatide, orginally an antidiabetic treatment which lowers blood sugar and slows down how quickly food is digested. GPs in England are being allowed to prescribe Mounjaro to severely obese people for the first time. Patients needed to be on weight loss programmes to get the drug previously. It will initially be offered to people with a body mass index (BMI) score of over 40 in the first year of the roll out. They will also have conditions such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Around 1.5m already take weight loss drugs in the UK, often through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: "This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health and greater access to weight loss drugs will make a significant difference to the lives of those people. "These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity. "They will be vital in helping some people lose weight and reduce their risk of serious long-term conditions." Anyone worried about their weight was urged to still speak with GPs and seek advice even if they were not eligible for the drug. Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: "We recognise the potential benefits of weight loss drugs. "But we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. "The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. "As and when this is escalated, appropriate resourcing for general practice, including access to 'wraparound' services, and training for GPs must follow." She added: "GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. "More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to focus on stopping people becoming overweight in the first place so they don't require medical intervention later." The rollout of the jabs should not "come at the expense of other weight loss services", she added. Olivier Picard, chairman of the National Pharmacy Association, told how demand for weight loss jabs continued to rise sharply. More GPs have been directing patients to local chemists to access these treatments privately. "We expect to see prescription volumes increase rapidly," he added. "However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. "We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. "The biggest concern we have is that prescribing these medications alone misses the point. They should be part of a comprehensive weight management strategy combining lifestyle coaching, exercise, and nutritional guidance. "In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends, simply because the foundational lifestyle changes weren't addressed." Around 29 percent of the adult population in the UK is obese. Health Secretary Wes Streeting warned that it is now one of the leading causes of ill health, costing the NHS billions. "Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity," he added. "Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best'. We are determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay." Why it works: Mounjaro is being rolled out gradually to those in greatest need following its success on the open market. It contains the drug Tirzepatide which not only helps the obese to lose weight, but reduces risk of other health conditions. The fall in the number of stroke and heart attack victims should save the NHS billions in the long term. Mounjaro is administered through a weekly injection. It was originally developed as a treatment for people with Type 2 diabetes. Regulators authorised its use for weight loss in November 2023 in a bid to tackle obesity. Tirzepatide acts in the same way as hormones GIP and GLP-1. They are produced in the intestine after eating and make you feel full. They also slow the passage of food through the gut which means patients feel satisfied for longer. Mounjaro 'pens' are for the abdomen or thighs if injecting yourself or the back of the upper arms if someone else is giving you the jab. Experts stress that it is not a 'miracle' drug and ideally needs to be combined with a reduced-calorie diet and exercise. It could potentially be prescribed for 3.4m in England over time. Side effects include nausea, diarrhoea, vomiting, constipation and indigestion.
